# Exploring Chemical Composition of the Aerial Parts of Vernoniastrum migeodii and Anti-Inflammatory Activity of the Compounds

**Authors:** Morteza Yazdani, Dóra Paróczai, Anita Barta, Katalin Burián, Judit Hohmann

PMC · DOI: 10.3390/plants15020321 · 2026-01-21

## TL;DR

This study identifies compounds in Vernoniastrum migeodii that may help reduce inflammation in epithelial cells, offering potential for treating inflammatory disorders.

## Contribution

The study is the first to explore the anti-inflammatory potential of V. migeodii compounds and their effects on epithelial inflammatory pathways.

## Key findings

- Compounds 2, 7, steroids 10–17, and aurantiamide acetate (18) reduced IL6 mRNA in LPS-activated A549 cells.
- (6S,9R)-vomifoliol (6) increased IL-6 and IL-8 levels in the same cell model.
- IL1β and PTGS2 transcripts were not significantly altered by the tested compounds.

## Abstract

Therapeutic strategies that fine-tune epithelial inflammatory responses are highly sought after in respiratory and mucosal disorders, but few molecules selectively target these pathways. Vernoniastrum migeodii (S. Moore) Isawumi (Asteraceae) represents a chemically promising but understudied source of bioactive small molecules. This study aimed to define the metabolite profile of V. migeodii and evaluate the modulation of inflammatory epithelial signaling of the constituents. From the methanolic extract of V. migeodii, five germacranolide sesquiterpenes, vernolide (1), 3′-hydroxylvernolide (2), pectorolide (3), 4′-hydroxypectorolide-14-O-acetate (4) and 4′-hydroxypectorolide (5), together with (6S,9R)-vomifoliol (6), eucarvone (7), luteolin (8), and luteolin-7-O-glucoside (9) were isolated by multiple chromatographic separations. The structures were determined by comprehensive 1D and 2D NMR spectroscopy. Isolated compounds 1 to 9 together with previously reported steroids (10–17) and tripeptide (18) were evaluated in LPS-activated A549 cells by quantitative PCR for interleukin-6 (IL6), interleukin-1β (IL1β), and prostaglandin-endoperoxide synthase 2 (PTGS2) and by enzyme-linked immunosorbent assay (ELISA) for IL-6 and IL-8. Compounds 2, 7, steroids 10–17 and aurantiamide acetate (18) reduced IL6 mRNA relative to the LPS control, while (6S,9R)-vomifoliol (6) increased IL-6 and elevated IL-8. In the assay IL1β and PTGS2 transcripts were not significantly altered. These findings highlight the potential of V. migeodii metabolites as modulators of epithelial inflammatory pathways. Combining chemical and biological evidence provides a clear basis for structure–activity- and pathway-focused studies.

## Linked entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569], IL1B (interleukin 1 beta) [NCBI Gene 3553], PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743]
- **Chemicals:** (6S,9R)-vomifoliol (PubChem CID 5280462), eucarvone (PubChem CID 136330), luteolin (PubChem CID 5280445), luteolin-7-O-glucoside (PubChem CID 5280637), aurantiamide acetate (PubChem CID 9832120)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}
- **Diseases:** respiratory and mucosal disorders (MESH:D012131), Inflammatory (MESH:D007249)
- **Chemicals:** 3'-hydroxylvernolide (-), luteolin (MESH:D047311), luteolin-7-O-glucoside (MESH:C066408), vernolide (MESH:C465363), (6S,9R)-vomifoliol (MESH:C525026), LPS (MESH:D008070), aurantiamide acetate (MESH:C011670), steroids (MESH:D013256)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12845201/full.md

---
Source: https://tomesphere.com/paper/PMC12845201